The spectrum of chronic hepatitis C virus infection in the Virginia correctional system: Development of a strategy for the evaluation and treatment of inmates with HCV

American Journal of Gastroenterology

Volumn 100, Issue 2, 2005, Pages 313-321

  Sterling, Richard K ^a   Brown Jr , Robert S ^b   Hofmann, Charlotte M ^b   Luketic, Velimir A ^b   Stravitz, Todd ^b   Sanyal, Arun J ^b   Contos, Melissa J ^b   Mills, A Scott ^b   Smith, Vernon ^b   Shiffman, Mitchell L ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN; BIOLOGICAL MARKER; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; FEMALE; GENOTYPE; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT RIGHT; PRIORITY JOURNAL; PRISON; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; BLOOD; CLASSIFICATION; DECISION TREE; ECONOMICS; GENETICS; HEALTH CARE COST; LIVER; NEEDLE BIOPSY; PATHOLOGY; PRISONER;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DECISION TREES; DRUG COSTS; FEMALE; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; PRISONERS; RNA, VIRAL; VIRGINIA;

EID: 20044374355     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40116.x     Document Type: Article

References (45)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Brown BS, Beschner GM. Handbook on risk of AIDS: Injection drug users and sexual partners. Wesport (CT): Greenwood Press, 1993: 338.
3. Spaulding A, Greene C, Davidson K, et al. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.
4. Holsen DS, Harthug S, Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug use and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis 1993;12:673-6.
5. Schwarz TF, Dobler G, Glich S, et al. Hepatitis C and arboviral antibodies in the island populations of Mauritius and Rodrigues. J Med Virol 1984;44:379-83.
6. Butler TG, Dolan KA, Person MJ, et al. Hepatitis B and C in New South Wales prisons: Prevalence and risk factors. Med J Aust 1997;166:127-30.
7. Malliori M, Sypsa V, Psichogiou M, et al. A survey of blood-borne viruses and associated risk behaviors in Greek prisons. Addiction 1998;93:243-51.
8. Anastassopoulou CG, Paraskevis D, Sypsa V, et al. Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. J Med Virol 1998;56:246-52.
9. Vlahov D, Nelson KE, Quinn TC, et al. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993;9:566-9.
10. Ruiz JD, Molitor F, Sun RK, et al. Prevalence and correlates of hepatitis C virus infection among inmates entering the California Correctional System. West J Med 1999;170:156-60.
11. Kendig NE. Hepatitis C management in correctional facilities. Prev Med Manag Care 2000;1:S33-41.
12. Hammett TM, Harmon P, Rhodes W. The burden of infectious disease among inmates and releases from correctional facilities. Prepared for The National Commission on Correctional Health Care-National Institute of Justice. A Health status of soon-to-be-released inmates@project. Presented at National Conference on Correctional Health; 1999; Ft. Lauderdale, FL, as a report in: Spotlight: Revealing the need for change: An interview with Robert Greifinger. HIV Education Prison Project News 1999;2:4-5.
13. Hammett TM, Harmon P, Rhodes W. The burden of infectious disease among inmates and releases from correctional facilities. Prepared for The National Commission on Correctional Health Care-National Institute of Justice. A Health status of soon-to-be-released inmates@project. Presented at National Conference on Correctional Health; 1999; Ft. Lauderdale, FL, as a report in: Spotlight: Revealing the need for change: An interview with Robert Greifinger. HIV Education Prison Project News 1999;2:4-5.
14. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for disease control and prevention. MMWR Recomm Rep 2003;52(RR-1):1-36.
15. Reindollar RW. Hepatis C and the correctional population. Am J Med 1999;107:100S-103S.
16. Seeff LB, Hollinger B, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
17. Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
18. Strader DB, Seeff LB. The natural history of chronic C hepatitis infection. Eur J Gastroenterol Hepatol 1996;8:324-8.
19. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression with chronic hepatitis C. Lancet 1997;349:825-32.
20. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
21. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection. Host, viral, and environmental factors. J Am Med Assoc 2000;284:450-6.
22. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications. Hepatology 2000;31:513-20.
23. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 2000;119:1385-96.
24. Reddy KR, Hoffnagle JH, Tong MJ, et al. Racial differences in response to therapy with Interferon in chronic hepatitis C. Hepatology 1999;30:787-93.
25. Wiley TE, Mika BP, McCarthy ME, et al. Pre-treatment differences between HCV-infected African Americans and non-African American patients (abstract). Hepatology 1999;30:417.
26. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
27. Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469-73.
28. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
29. Fried MW, Shiftman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
30. Hadziyannis SJ, Sette H, Morgan T, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
31. Levine RA. Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time. Ann Intern Med 1998;129:323-6.
32. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001;33:196-200.
33. Wong JB, Poynard T, Ling MH, et al. Cost effectiveness of 24 or 48 weeks of interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000;95:1524-30.
34. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effective analysis. Ann Intern Med 2000;133:665-75.
35. Leigh JP, Bowles CL, Leistikow BN, et al. Costs of hepatitis C. Arch Intern Med 2001;161:2231-7.
36. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA 1998;280:2088-93.
37. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S179-84.
38. Zeuzum S, Diago M, Gane E, et al. International multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) and ribavirin. Hepatology 2003;38:208A (abstract 106).
39. Poynard T, McHutchinson J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
40. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
41. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
42. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426-32.
43. McHutchinson JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-23.
44. Sterling RK, Hofmann CM, Luketic VA, et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: Can compliance overcome racial differences to response. Am J Gastroenterol 2004;99:866-72.
45. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-90.